** Shares of SomnoMed SOM.AX rise 6.7% to A$0.64
** Stock rose as much as 10% to A$0.66, its highest level since Aug 21, 2023
** Medical device manufacturer upgrades EBITDA forecast at A$7 mln-A$9 mln ($4.40 mln-$5.65 mln) for fiscal 2025, from previous forecast of A$7 mln
** Co, specialising in sleep disorders, logs group revenue A$28.5 mln for Q2 vs A$23.7 mln from the same period last year
** More than 257,000 shares change hands vs 30-day avg volume of around 166,000 shares
** Stock down 38% YTD, including current session's moves
($1 = 1.5924 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。